Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.4691
−$0.0184 · -3.77%
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
Previous close
$0.4691
−$0.0184 · -3.77%
After-hours
$0.479
+$0.0099 · +2.11%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
Day range
Current $0.4691
52-week range
Current $0.4691
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
50
Fair Value
Sentiment
56
Mixed
Risk
70
High Risk
Momentum
35
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
Day range
Current $0.4691
52-week range
Current $0.4691
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 1.06M USD | 2.13M USD | 6.91M USD | 1.58M USD | 82.04K USD |
| Selling, general, and administrative | 2.17M USD | 2.09M USD | 2.52M USD | 2.09M USD | 1.02M USD |
| Operating expenses | 3.23M USD | 4.22M USD | 9.43M USD | 3.67M USD | 1.1M USD |
| Interest income | 121.98K USD | 55.66K USD | 1.87K USD | — | 805.11 USD |
| Interest expense | — | — | — | 731.71K USD | 805.11K USD |
| Depreciation and amortization | — | 4.22M USD | 9.43M USD | — | — |
| Operating income | −3.23M USD | −4.22M USD | −9.43M USD | −3.67M USD | −1.1M USD |
| Net income | −3.11M USD | −4.11M USD | −8.95M USD | −1.48M USD | −1.61M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 10, 2025 | 1:6 | — | — |
Stock split | Dec 20, 2023 | 1:8 | — | — |
Stock split | Jun 7, 2023 | 1:30 | — | — |
Stock split | Oct 13, 2021 | 1:2 | — | — |
Stock split | Nov 2, 2020 | 1:10 | — | — |
Stock split | Jul 24, 2018 | 1:10 | — | — |
Effective Jun 10, 2025
1:6
Effective Dec 20, 2023
1:8
Effective Jun 7, 2023
1:30
Effective Oct 13, 2021
1:2
Effective Nov 2, 2020
1:10
Effective Jul 24, 2018
1:10
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
